Owen A O'Connor

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Targeting histones and proteasomes: new strategies for the treatment of lymphoma
    Owen A O'Connor
    Department of Medicine, Lymphoma and Developmental Chemotherapy Services, Box 329, 1275 York Ave, New York, NY 1002, USA
    J Clin Oncol 23:6429-36. 2005
  2. ncbi New drugs for the treatment of advanced-stage diffuse large cell lymphomas
    Owen A O'Connor
    Laboratory of Experimental Therapeutics for the Lymphoproliferative Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Hematol 43:251-61. 2006
  3. ncbi Pralatrexate: an emerging new agent with activity in T-cell lymphomas
    Owen A O'Connor
    Laboratory of Experimental Therapeutics for Lymphoproliferative Malignancies, Department of Medicine, Division of Hematologic Malignancies, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Curr Opin Oncol 18:591-7. 2006
  4. ncbi The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide
    Owen A O'Connor
    Department of Medicine, Lymphoma, and Developmental Chemotherapy Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 12:2902-11. 2006
  5. ncbi Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma
    Owen A O'Connor
    Memorial Sloan Kettering Cancer Center, Department of Medicine, New York, NY 10021, USA
    Clin Lymphoma Myeloma 6:191-9. 2005
  6. ncbi Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies
    Owen A O'Connor
    Department of Medicine, Division of Hematologic Oncology, Lymphoma Service, Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute, New York, NY 10021, USA
    J Clin Oncol 24:166-73. 2006
  7. ncbi Comparative animal models for the study of lymphohematopoietic tumors: strengths and limitations of present approaches
    Owen A O'Connor
    Laboratory of Experimental Therapeutics for Lymphoproliferative Malignancies, Memorial Sloan Kettering Cancer Center
    Leuk Lymphoma 46:973-92. 2005
  8. ncbi The emerging role of bortezomib in the treatment of indolent non-Hodgkin's and mantle cell lymphomas
    Owen A O'Connor
    Department of Medicine, Division of Hematologic Malignancies, Lymphoma and Developmental Chemotherapy Services, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Curr Treat Options Oncol 5:269-81. 2004
  9. ncbi Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma
    Owen A O'Connor
    Department of Medicine, Lymphoma and Developmental Chemotherapy Services, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:676-84. 2005
  10. doi The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies
    Luca Paoluzzi
    Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA
    Blood 112:2906-16. 2008

Detail Information

Publications57

  1. ncbi Targeting histones and proteasomes: new strategies for the treatment of lymphoma
    Owen A O'Connor
    Department of Medicine, Lymphoma and Developmental Chemotherapy Services, Box 329, 1275 York Ave, New York, NY 1002, USA
    J Clin Oncol 23:6429-36. 2005
    ..In this article, we will review some of the prevailing theories about how these novel targeted drugs affect lymphoma biology, and how these compounds are changing the face of lymphoma therapy...
  2. ncbi New drugs for the treatment of advanced-stage diffuse large cell lymphomas
    Owen A O'Connor
    Laboratory of Experimental Therapeutics for the Lymphoproliferative Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Hematol 43:251-61. 2006
    ....
  3. ncbi Pralatrexate: an emerging new agent with activity in T-cell lymphomas
    Owen A O'Connor
    Laboratory of Experimental Therapeutics for Lymphoproliferative Malignancies, Department of Medicine, Division of Hematologic Malignancies, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Curr Opin Oncol 18:591-7. 2006
    ..Pralatrexate is a novel antifolate designed to have high affinity for the reduced folate carrier type 1 (RFC-1). Preclinical and clinical studies have demonstrated that pralatrexate has significant activity against TCL...
  4. ncbi The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide
    Owen A O'Connor
    Department of Medicine, Lymphoma, and Developmental Chemotherapy Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 12:2902-11. 2006
    ..To determine whether the combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen can sensitize human lymphoma to cyclophosphamide...
  5. ncbi Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma
    Owen A O'Connor
    Memorial Sloan Kettering Cancer Center, Department of Medicine, New York, NY 10021, USA
    Clin Lymphoma Myeloma 6:191-9. 2005
    ..Herein, some of the biologic rationale for using proteasome inhibitors in lymphoma as well as some of the clinical data from these promising studies are discussed...
  6. ncbi Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies
    Owen A O'Connor
    Department of Medicine, Division of Hematologic Oncology, Lymphoma Service, Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute, New York, NY 10021, USA
    J Clin Oncol 24:166-73. 2006
    ..To document the toxicity and activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in patients with pretreated hematologic malignancies...
  7. ncbi Comparative animal models for the study of lymphohematopoietic tumors: strengths and limitations of present approaches
    Owen A O'Connor
    Laboratory of Experimental Therapeutics for Lymphoproliferative Malignancies, Memorial Sloan Kettering Cancer Center
    Leuk Lymphoma 46:973-92. 2005
    ..In this article, we will review the numerous complexities associated with various animal models of lymphoma, and will try to explore several alternative models which might serve as better in vivo...
  8. ncbi The emerging role of bortezomib in the treatment of indolent non-Hodgkin's and mantle cell lymphomas
    Owen A O'Connor
    Department of Medicine, Division of Hematologic Malignancies, Lymphoma and Developmental Chemotherapy Services, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Curr Treat Options Oncol 5:269-81. 2004
    ..The story is testament to the value of recognizing the importance of empiric observations in clinical and preclinical investigations...
  9. ncbi Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma
    Owen A O'Connor
    Department of Medicine, Lymphoma and Developmental Chemotherapy Services, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:676-84. 2005
    ..To determine the antitumor activity of the novel proteasome inhibitor bortezomib in patients with indolent and mantle-cell lymphoma (MCL)...
  10. doi The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies
    Luca Paoluzzi
    Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA
    Blood 112:2906-16. 2008
    ..Collectively, these data suggest that ABT-737 alone or in combination with a proteasome inhibitor represents a novel and potentially important platform for the treatment of B-cell malignancies...
  11. doi Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma
    Luca Paoluzzi
    Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York, USA
    Clin Cancer Res 16:554-65. 2010
    ..They are also known to be prodifferentiating. Mantle cell lymphoma (MCL) is an aggressive subtype of non-Hodgkin lymphoma characterized by the t(11;14)(q13;q32) translocation leading to the overexpression of cyclin D1...
  12. doi Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phas
    Owen A O'Connor
    Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA
    Br J Haematol 145:34-9. 2009
    ..Importantly, these data suggest that MCL patients with refractory or poorly responsive disease may still derive meaningful clinical benefit from treatment with bortezomib...
  13. doi Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes
    Owen A O'Connor
    NYU Cancer Institute, NYU Langone Medical Center, New York, New York, USA
    Clin Cancer Res 16:719-26. 2010
    ..To determine the antitumor activity of the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma...
  14. ncbi R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy
    Jeffrey L Halaas
    Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Leuk Lymphoma 46:541-7. 2005
    ..Whether adding rituximab and increasing dose intensity improves survival over either alone will require randomized studies...
  15. doi Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma
    John Gerecitano
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York 10065, USA
    Clin Cancer Res 17:2493-501. 2011
    ....
  16. pmc Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma
    Craig H Moskowitz
    Departments of Medicine, Radiology, Pathology, and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 28:1896-903. 2010
    ..Outside of a clinical trial, we recommend biopsy confirmation of an abnormal interim FDG-PET scan before changing therapy...
  17. doi A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma
    Owen A O'Connor
    Department of Medicine, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, Lymphoma Service, New York, NY 10032, USA
    Br J Haematol 143:201-9. 2008
    ..The duration of response ranged from 2 to 8 months. Major toxicities included fatigue, myelosuppression and neuropathy. These data suggest that Ixabepilone has activity in chemotherapy-refractory lymphoma...
  18. doi Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma
    John Gerecitano
    Department of Medicine, Memorial Sloan Kettering Cancer Center, Columbia University, New York, NY 10021, USA
    Br J Haematol 146:652-5. 2009
    ..The weekly schedule of bortezomib was less toxic, but yielded fewer and lower quality responses than twice-weekly bortezomib. Given the similar PFS, the weekly schedule may still be appropriate for some patients...
  19. ncbi The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma
    Lorraine E Toner
    Laboratory of Experimental Therapeutics for the Lymphoproliferative Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 12:924-32. 2006
    ....
  20. pmc Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies
    Owen A O'Connor
    Lymphoid Development and Malignancy Program, Lymphoma Service, Columbia University, Herbert Irving Comprehensive Cancer Center, 1130 St Nicholas Ave, New York, NY 10032, USA
    J Clin Oncol 27:4357-64. 2009
    ..To determine the maximum-tolerated dose (MTD) and efficacy of pralatrexate in patients with lymphoma...
  21. doi Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma
    Steven M Horwitz
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    Blood 119:4115-22. 2012
    ..The most common grade 3 adverse event (AE) was mucositis (17%); the only grade 4 AE was leukopenia (3%). Pralatrexate 15 mg/m(2)/wk for 3/4 weeks shows high activity with acceptable toxicity in patients with relapsed/refractory CTCL...
  22. doi The anti-histaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor
    Luca Paoluzzi
    Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA
    Br J Haematol 146:656-9. 2009
    ..In a severe combined immunodeficient beige mouse model, cyproheptadine plus bortezomib demonstrated a statistically significant advantage compared to either agent alone...
  23. doi Pralatrexate-induced tumor cell apoptosis in the epidermis of a patient with HTLV-1 adult T-cell lymphoma/leukemia causing skin erosions
    Alexander G Marneros
    Department of Dermatology, Columbia Presbyterian Medical Center, New York, NY, USA
    Blood 113:6338-41. 2009
    ..This distinction is critical and may profoundly influence the clinical decision to continue pralatrexate treatment. Pralatrexate-induced skin erosions may indicate response to treatment...
  24. ncbi Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma
    Owen A O'Connor
    Lymphoma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, NY 10032, USA
    Br J Haematol 139:425-8. 2007
    ..For each TCL patient, the response was more durable than their best response with chemotherapy. This early experience is the first to document this unique activity of pralatrexate in TCL...
  25. ncbi Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?
    John Gerecitano
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Br J Haematol 134:391-8. 2006
    ..In fact, the development of an isolated cutaneous vasculitis may portend a better clinical response to bortezomib in some patients...
  26. doi Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma
    Luca Paoluzzi
    Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA
    Blood 111:5350-8. 2008
    ..The addition of AT-101 to cyclophosphamide (Cy) and rituximab (R) in a schedule-dependent manner enhanced the efficacy of the conventional therapy...
  27. pmc HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL
    Matko Kalac
    New York University Cancer Institute, New York University Langone Medical Center, 522 First Avenue, New York, NY 10016, USA
    Blood 118:5506-16. 2011
    ..Among the genes uniquely altered by the combination of panobinostat and decitabine were VHL, TCEB1, WT1, and DIRAS3...
  28. ncbi Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies
    Robert Z Orlowski
    Lineberger Comprehensive Cancer Center, Department of Medicine, University of North Carolina at Chapel Hill, 27599 7295, USA
    J Clin Oncol 20:4420-7. 2002
    ..To determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacodynamics (PD) of the proteasome inhibitor bortezomib (previously known as PS-341) in patients with refractory hematologic malignancies...
  29. pmc Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs
    Mark L Heaney
    Departments of Medicine and Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Res 68:8031-8. 2008
    ..These results support the hypothesis that vitamin C supplementation during cancer treatment may detrimentally affect therapeutic response...
  30. doi Novel agents in development for peripheral T-cell lymphoma
    Owen A O'Connor
    New York University Cancer Institute, NYU Langone Medical Center, New York, NY, USA
    Semin Hematol 47:S11-4. 2010
    ....
  31. doi High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging
    Craig H Moskowitz
    Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Br J Haematol 148:890-7. 2010
    ..61. Risk-adapted augmentation of salvage treatment in patients with HL is feasible and improves EFS in poorer-risk patients. Our data suggest that normalisation of FI pre-ASCT predicts outcome, and should be the goal of salvage treatment...
  32. doi Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies
    Enrica Marchi
    New York University Cancer Institute, NYU Langone Medical Center, New York, New York 10016, USA
    Clin Cancer Res 16:3648-58. 2010
    ..Based on the PROPEL data, pralatrexate was the first drug approved for patients with relapsed and refractory peripheral T-cell lymphoma. Bortezomib is a proteasome inhibitor that has shown some activity in patients with T-cell lymphoma...
  33. ncbi Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas
    Luca Paoluzzi
    Laboratory of Experimental Therapeutics for the Lymphoproliferative Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    BioDrugs 20:13-23. 2006
    ..We will undoubtedly need to understand these effects better in order to fully exploit the potential of this new class of drugs...
  34. ncbi Histone deacetylase inhibitors: from target to clinical trials
    William K Kelly
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Expert Opin Investig Drugs 11:1695-713. 2002
    ..Several HDAC inhibitors are currently in clinical trials as anticancer agents and, in particular, hydroxamic acid-based HDAC inhibitors have shown activity against cancers at well-tolerated doses...
  35. ncbi Targeting survival pathways in lymphoma
    Luca Paoluzzi
    Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, The New York Presbyterian Hospital, Columbia University, New York, USA
    Adv Exp Med Biol 687:79-96. 2010
    ..Appropriate preclinical studies will need to identify the optimal strategies for combining these agents, with an emphasis on the importance of dose and schedule dependency...
  36. pmc Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer
    William Kevin Kelly
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Joan and Sanford Weill Medical College of Cornell University, New York, NY 10021, USA
    J Clin Oncol 23:3923-31. 2005
    ..To determine the safety, dosing schedules, pharmacokinetic profile, and biologic effect of orally administered histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in patients with advanced cancer...
  37. doi New drugs for the treatment of lymphoma
    Luca Paoluzzi
    Herbert Irving Comprehensive Cancer Center, Columbia University, 1130 St Nicholas Avenue, Room 216, New York, NY 10032, USA
    Hematol Oncol Clin North Am 22:1007-35, x. 2008
    ..The article focuses on the many new targets including Syk, Bcl-2, CD-40, and the phosphoinositide-3 kinase/AKT/mammalian target of rapamycin pathway...
  38. doi A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies
    Owen A O'Connor
    NYU Cancer Institute, NYU Langone Medical Center, 522 First Ave, Smilow 1101, New York, NY, USA
    Clin Cancer Res 15:7085-91. 2009
    ..Proteasome inhibition by carfilzomib is mechanistically irreversible. Consequently, proteasome inhibition is more sustained with carfilzomib than with bortezomib...
  39. ncbi Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas
    Carol Aghajanian
    Developmental Chemotherapy Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:1082-8. 2007
    ..Dosing schedules of 40 mg/m2 and 50 mg/m2 over 3 hours were also evaluated...
  40. pmc Noninvasive phosphorus magnetic resonance spectroscopic imaging predicts outcome to first-line chemotherapy in newly diagnosed patients with diffuse large B-cell lymphoma
    Fernando Arias-Mendoza
    Department of Radiology, Columbia University, 710 W 168th St, Neurological Institute Basement, Room B 057, New York, NY 10032, USA
    Acad Radiol 20:1122-9. 2013
    ....
  41. doi Brentuximab vedotin
    Changchun Deng
    Center for Lymphoid Malignancies, Columbia University Medical Center, New York, NY 10022, USA
    Clin Cancer Res 19:22-7. 2013
    ..The mechanism of action, preclinical antitumor activity, and clinical activity of brentuximab vedotin against Hodgkin lymphoma, ALCL, and other CD30-expressing lymphomas are reviewed...
  42. ncbi Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma
    Jason Konner
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Invest New Drugs 30:2294-302. 2012
    ..To determine the maximum tolerated dose and safety of the epothilone, KOS-862, in patients with advanced solid tumors or lymphoma...
  43. pmc Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study
    Owen A O'Connor
    New York University NYU Cancer Institute, NYU Langone Medical Center, New York, NY, USA
    J Clin Oncol 29:1182-9. 2011
    ..Peripheral T-cell lymphoma (PTCL) is a poor prognosis subtype of non-Hodgkin's lymphoma with no accepted standard of care. This study evaluated the efficacy and tolerability of pralatrexate, a novel antifolate with promising activity...
  44. ncbi Novel small molecules in the treatment of lymphomas
    John Gerecitano
    Memorial Sloan Kettering Cancer Center, Department of Medicine, Division of Hematologic Oncology, Lymphoma and Developmental Chemotherapy Services, New York, NY, USA
    Cancer Treat Res 131:413-60. 2006
  45. doi Murine models in mantle cell lymphoma
    Kelly Zullo
    Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center and New York Presbyterian Hospital, New York, NY 10032, USA
    Best Pract Res Clin Haematol 25:153-63. 2012
    ....
  46. ncbi Pegylated interferon plus rituximab in advanced stage, indolent lymphoma: is there CD20 antigen upregulation?
    Carol S Portlock
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Leuk Lymphoma 47:1260-4. 2006
    ..9%). PegIFN plus rituximab as delivered in this study is not recommended. PegIFN does not appear to upregulate CD20 expression in peripheral lymph node tumor cells...
  47. doi Acute orbitocranial inflammation following radioimmunotherapy for non-Hodgkin lymphoma
    John C Hwang
    Edward S Harkness Eye Institute, Columbia University Medical Center, New York, New York 10032, USA
    Ophthal Plast Reconstr Surg 26:210-2. 2010
    ..Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan may result in hemorrhagic tumor necrosis with acute orbital and intracranial inflammation...
  48. doi New therapeutic targets and drugs in non-Hodgkin's lymphoma
    Ahmed Sawas
    NYU Cancer Institute, School of Medicine, NYU Langone Medical Center, New York, New York 10016, USA
    Curr Opin Hematol 18:280-7. 2011
    ..Advances in our understanding of lymphoma biology and molecular pathogenesis are yielding new therapeutic targets...
  49. doi Mantle cell lymphoma in relapse: the role of emerging new drugs
    Catherine S M Diefenbach
    New York University Cancer Institute, NYU Langone Medical Center, New York, NY, USA
    Curr Opin Oncol 22:419-23. 2010
    ..Advances in our understanding of the molecular pathogenesis of MCL are yielding many promising novel therapies...
  50. doi A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: a multicenter clinicopathologic experience and new prognostic score
    Adrienne A Phillips
    Division of Medical Oncology, Department of Medicine, Columbia University College of Physicians and Surgeons, Milstein Hospital Building, New York, New York 10032, USA
    Cancer 116:3438-46. 2010
    ....
  51. doi Pralatrexate pharmacology and clinical development
    Enrica Marchi
    Authors Affiliations Department of Medicine, Center for Lymphoid Malignancies, Columbia University Medical Center and Tisch Cancer Institute, Mount Sinai School of Medicine, New York, New York
    Clin Cancer Res 19:6657-61. 2013
    ..These insights are leading to a number of novel phase I and II combination studies which could challenge existing regimens like CHOP, and improve the outcome of patients with T-cell lymphoma...
  52. pmc Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma
    Lapo Alinari
    Division of Hematology, Department of Medicine, College of Medicine, The Ohio State University, Columbus, USA
    Blood 117:4530-41. 2011
    ..Significant in vivo therapeutic activity of combination rituximab and milatuzumab was demonstrated in a preclinical model of MCL. These data support clinical evaluation of combination milatuzumab and rituximab therapy in MCL...
  53. doi Bone marrow involvement in patients with posttransplant lymphoproliferative disorders: incidence and prognostic factors
    Francesca Montanari
    Department of Internal Medicine Division of Hematology Oncology, Columbia University, New York, NY 10032, USA
    Hum Pathol 41:1150-8. 2010
    ....
  54. pmc Safety and efficacy of pralatrexate in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma
    Enrica Marchi
    Associate Research Scientist, Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center, New York, NY 10032, USA
    Ther Adv Hematol 3:227-35. 2012
    ..clinical development, pralatrexate, preclinical data, T-cell lymphoma...
  55. doi New strategies in the treatment of mantle cell lymphoma
    Changchun Deng
    Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center, New York, New York 10022, USA
    Clin Cancer Res 18:3499-508. 2012
    ..Here, we discuss many of these developments and how they may potentially affect the natural history of this disease...
  56. pmc Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma
    Salvia Jain
    NYU Cancer Institute, Division of Hematology and Medical Oncology, NYU Langone Medical Center, New York, NY, USA
    Core Evid 6:43-57. 2011
    ..This review focuses on the pharmacology, safety, and efficacy of carfilzomib for the treatment of multiple myeloma in bortezomib-naïve and bortezomib-exposed populations...
  57. pmc Targeting histone deacetyalses in the treatment of B- and T-cell malignancies
    Jasmine Zain
    NYU Clinical Cancer Center, 160 East 34th Street, New York, NY 10016, USA
    Invest New Drugs 28:S58-78. 2010
    ..HDAC inhibitors will likely be incorporated into combinations of targeted therapies both in the upfront and relapsed setting for lymphomas...